HBOT and graft survival in women

Has HBOT after a hair transplant been studied in women?

No. There is no published research on hyperbaric oxygen therapy after hair transplantation in women — not a randomised trial, a subgroup analysis, or a case series. This is a genuine evidence gap, not something reasoning can fill in, and it matters more for female patients than it might first appear.

Has anyone raised the lack of female-specific HBOT data in print?

Yes. Dong and Jin wrote to the Journal of Cosmetic Dermatology after Fan's trial, noting it did not describe whether outcomes differed by sex — calling this 'indispensable' given how much androgen levels differ between men and women. They flagged that hair-loss medication use was unspecified in the exclusion criteria. Neither point was resolved.

It is worth noting that the absence was flagged by other researchers rather than only by us. When Fan and colleagues published their randomised trial, Dong and Jin wrote to the Journal of Cosmetic Dermatology raising methodological questions, and one of the two they raised was precisely this: the original article did not clearly describe whether the outcome difference between the control and HBOT groups differed by sex.

Their reasoning was that androgen levels differ substantially between male and female patients with androgenetic alopecia, and that a sex-stratified result was, in their words, indispensable for evaluating the study. They also noted that the use of hair-loss medication was not clearly explained in the exclusion criteria — a second variable that differs systematically between male and female patients, since Finasteride and Dutasteride are not standard treatments for women.

Neither point was resolved in the published exchange. So the single randomised trial in this field has an acknowledged, unaddressed uncertainty about whether its result applies to women at all.

How does hair transplantation in women differ in ways that could affect HBOT's results?

Female transplants often place grafts among existing hair in a diffusely thinning mid-scalp, using no-shave techniques that lengthen how long grafts sit outside the body. Women are usually not on Finasteride or Dutasteride, unlike most male participants, and often have non-androgenetic causes and shock loss of native hair — none addressed by any HBOT study.

This is not merely a matter of statistical caution. Several features of hair transplantation in women differ in ways that plausibly interact with anything aimed at graft survival.

• Pattern and recipient environment. Female pattern hair loss is typically diffuse thinning over the mid-scalp rather than a bald recipient zone. Grafts are frequently placed among existing hair, in a bed with different vascularity and different surgical constraints.
• No-shave technique. Many women undergo no-shave or partial-shave procedures, which change extraction and placement handling and lengthen the time grafts spend outside the body.
• Medication differences. Male patients are commonly on Finasteride or Dutasteride around the time of surgery; women generally are not. Since post-operative shedding was the endpoint where the trial found its effect, differing background medication is not a trivial confounder.
• Underlying cause. Female hair loss more often has a component beyond androgenetic alopecia — telogen effluvium, iron deficiency, thyroid disease, traction — which affects both candidacy and the healing environment.
• Shock loss. Placing grafts among existing hair carries a recognised risk of temporary shedding of surrounding native hair, which is a different phenomenon from the shedding of transplanted shafts that the trial measured.

What should a female patient conclude from the HBOT trial numbers?

The Fan trial's figures — 27.6% versus 69.1% early shedding, 11.8% versus 35.3% itching and folliculitis, and a non-significant 96.9% versus 93.8% survival difference — come from a 34-patient sample without a reported sex breakdown. If a clinic quotes them, it is fair to ask how many women were included; the paper does not say.

The findings from the Fan trial — 27.6% versus 69.1% early shedding, 11.8% versus 35.3% itching and folliculitis, and a nine-month survival difference of 96.9% versus 93.8% that was not statistically significant — come from a mixed 34-patient sample whose sex breakdown was not reported in a usable form.

If those numbers are quoted to you as a reason to buy chamber sessions, it is entirely fair to ask how many women were in the trial and what happened to them. The published paper does not answer that.

That does not mean HBOT cannot help female patients. It means nobody has shown that it does, and the usual caveat about small trials applies with an extra layer on top.

What questions should a female patient ask instead of focusing on HBOT?

For women, the higher-impact questions are whether hair loss has been investigated beyond androgenetic causes, whether the donor area is stable given that diffuse thinning can affect it, how the surgeon will protect existing hair during placement, and what the plan is for native hair not being transplanted — all matter more than any adjunct.

For women considering a transplant, the variables that most reliably determine the result are not adjuncts.

• Has the cause of the hair loss been properly investigated, including the non-androgenetic causes?
• Is the donor area stable enough to support the plan, given that diffuse thinning can affect the donor zone too?
• How will the surgeon protect the existing hair in the recipient area during placement?
• What is the plan for the native hair that is not being transplanted?

Those questions have larger effects on the twelve-month result than any post-operative adjunct that has been studied.

Sources

1. Dong X, Jin X. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia [letter to the editor]. Journal of Cosmetic Dermatology, 2021. doi.org/10.1111/jocd.14131
2. Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
3. Parsley WM, Perez-Meza D. Review of factors affecting the growth and survival of follicular grafts. Journal of Cutaneous and Aesthetic Surgery, 2010;3(2). jcasonline.com
4. Giardiello F, De Medeiros Quirino L, Brigante R, Chumak M. Hyperbaric Oxygen Therapy for Enhanced Postoperative Recovery in Hair Transplantation. Cureus, 2025;17(12):e99635. doi.org/10.7759/cureus.99635

This article summarises published research and standard clinical practice. It is general educational information, not medical advice, and it does not replace the instructions your own surgical team gives you. Where their guidance differs from anything here, follow theirs.